【24h】

Manipulation of BCG vaccine: a double-edged sword

机译:操纵BCG疫苗:双刃剑

获取原文
获取原文并翻译 | 示例
       

摘要

Mycobacterium bovis Bacillus Calmette-Gu,rin (BCG), an attenuated vaccine derived from M. bovis, is the only licensed vaccine against tuberculosis (TB). Despite its protection against TB in children, the protective efficacy in pulmonary TB is variable in adolescents and adults. In spite of the current knowledge of molecular biology, immunology and cell biology, infectious diseases such as TB and HIV/AIDS are still challenges for the scientific community. Genetic manipulation facilitates the construction of recombinant BCG (rBCG) vaccine that can be used as a highly immunogenic vaccine against TB with an improved safety profile, but, still, the manipulation of BCG vaccine to improve efficacy should be carefully considered, as it can bring in both favourable and unfavourable effects. The purpose of this review is not to comprehensively review the interaction between microorganisms and host cells in order to use rBCG expressing M. tuberculosis (Mtb) immunodominant antigens that are available in the public domain, but, rather, to also discuss the limitations of rBCG vaccine, expressing heterologous antigens, during manipulation that pave the way for a promising new vaccine approach.
机译:细胞杆菌Bacils Bacillus albette-gu,rin(bcg),衍生自M. bovis的减毒疫苗,是唯一对结核病(Tb)的许可疫苗。尽管其对儿童TB的保护,但肺结核中的保护效果是青少年和成人的可变性。尽管目前关于分子生物学,免疫学和细胞生物学的知识,但TB和艾滋病毒/艾滋病等传染病对科学界仍然挑战。遗传操作促进重组BCG(RBCG)疫苗的构建,其可用作避免TB的高度免疫原性疫苗,并且仍然需要仔细考虑BCG疫苗以提高疗效的操纵,因此可以提高在有利和不利的影响。本综述的目的不是全面地审查微生物和宿主细胞之间的相互作用,以便使用在公共领域中可用的Cuberculosis(MTB)的抗原的RBCG,而是讨论RBCG的局限性疫苗,表达异源抗原,在操纵过程中为有前途的新疫苗方法铺平道路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号